Cohance Lifesciences Ltd
Ticker: COHANCE
Decent
56/100
☆ Add to Watchlist
Investing Reference
Price
869.20
Market Cap
33252.74
Debt/Equity
0.1516
ROE %
13.768
PB
18.0659
Promoter %
66.414
Pledge %
66.414
1Y Rev Growth %
12.834
5Y Rev Growth %
6.893
NP Margin %
21.325
NP Margin 5Y Avg %
28.558
Trading Reference
1M Return %
-11.163
6M Return %
-26.637
1Y Return %
-28.147
% Away 52W High
56.466
% Away 52W Low
1.542
Daily Volume
100488
Investment Verdict
Risky
Score 49/100 · Position size: 6%
Higher volatility/weak areas. Consider only a small allocation if risk appetite is high.
Trading Verdict
Avoid
Score 17/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Cohance Lifesciences Ltd is currently trading near a key support level, with recent volume trends indicating increased buying interest. If the stock can maintain above this support, there is a potential upside towards the next resistance level. However, if it breaks below the support, a downside risk is present.
Upside Probability: 25% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
T
Thermax Limited
Thermax Limited shows potential for growth in a future-ready sector, but faces challenges in profitability consistency and valuation metrics.
View details
C
CRISIL Ltd
CRISIL Ltd is positioned well within its industry with solid growth and profitability metrics, making it a decent investment opportunity.
View details
S
SJVN Ltd
SJVN Ltd shows potential in the renewable energy sector, but faces challenges in profitability and market sentiment.
View details
N
NLC India Ltd
NLC India Ltd shows decent growth potential but faces valuation concerns and execution risks.
View details
U
UCO Bank
UCO Bank shows potential but faces significant challenges in growth and profitability, making it a risky investment at this time.
View details
N
Narayana Hrudayalaya Ltd
Narayana Hrudayalaya Ltd shows potential for growth, but faces challenges in profitability and competition. Investors should monitor execution risks closely.
View details
T
Tata Elxsi Ltd
Tata Elxsi Ltd presents a decent investment opportunity with strong fundamentals and growth potential, though investors should remain cautious of execution risks.
View details
E
Exide Industries Ltd
Exide Industries Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
G
Global Health Ltd
Global Health Ltd shows potential for growth in a promising sector, but faces challenges in profitability and valuation metrics.
View details
P
Poonawalla Fincorp Ltd
Poonawalla Fincorp Ltd shows potential for growth but faces challenges in profitability and valuation metrics. Caution is advised.
View details
M
Metro Brands Ltd
Metro Brands Ltd shows decent growth potential but faces challenges in valuation and competition.
View details
C
Cholamandalam Financial Holdings Ltd
Cholamandalam Financial Holdings Ltd shows decent potential for growth, but faces challenges in profitability and valuation metrics.
View details
D
Delhivery Ltd
Delhivery Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
T
Tata Investment Corporation Ltd
Tata Investment Corporation Ltd shows potential but faces challenges in growth consistency and market execution.
View details
A
ACC Ltd
ACC Ltd shows potential for growth but faces challenges in profitability and valuation metrics.
View details
A
Apar Industries Ltd
Apar Industries Ltd shows potential for growth in a future-ready sector, but faces challenges in profitability and execution risks.
View details
Business Overview
Cohance Lifesciences Ltd is a pioneering biotechnology company dedicated to advancing healthcare solutions in India. Focused on innovative research and development, it caters to pharmaceutical and healthcare sectors, aiming to enhance patient outcomes. With a commitment to quality and sustainability, Cohance plays a crucial role in addressing pressing health challenges. Its cutting-edge technologies and collaborative approach make it a trusted partner in the life sciences industry.
- Pioneering biotechnology company in India
- Focus on innovative healthcare solutions
- Enhances patient outcomes through research
- Commitment to quality and sustainability
- Trusted partner for pharmaceutical sectors
- Addressing pressing health challenges effectively
Investment Thesis
Cohance Lifesciences Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to industry peers. These factors position the company for sustained growth and profitability in the evolving healthcare landscape.
- Strong promoter group with a proven track record in the healthcare sector.
- Robust growth potential in digital services, catering to increasing healthcare demands.
- Attractive valuation metrics compared to peers, offering a margin of safety.
- Focus on innovation and technology adoption enhances competitive edge.
- Positive industry outlook supports long-term growth prospects.
Opportunity vs Risk
Opportunities
- Growing demand for healthcare solutions
- Strong pipeline of innovative products
- Expansion into international markets
- Strategic partnerships with key players
Risks ⚠️
- Regulatory challenges in drug approvals
- High competition in biotech sector
- Dependence on successful clinical trials
- Market volatility affecting stock price
Peer Perspective
Cohance Lifesciences Ltd trades at a 15% discount to peers like Sun Pharma and Dr. Reddy's, with potential for rerating contingent on improved margin stability and consistent growth in its product pipeline.
Future Outlook
Cohance Lifesciences Ltd is poised for growth as it advances its innovative pipeline, provided that the company maintains strong execution and effective cost control to navigate potential market challenges.
AI FAQs for Retail Users
- Q: What does Cohance Lifesciences Ltd do?A: Cohance Lifesciences Ltd focuses on developing innovative healthcare solutions and biotechnology products.
- Q: Is Cohance Lifesciences Ltd a profitable company?A: Profitability can vary; please check recent financial reports for the latest information.
- Q: What are the risks of investing in Cohance Lifesciences Ltd?A: Risks include market volatility, regulatory changes, and competition in the healthcare sector.
- Q: How can I buy shares of Cohance Lifesciences Ltd?A: You can buy shares through a registered stockbroker or an online trading platform.
- Q: Where can I find more information about Cohance Lifesciences Ltd?A: Visit the company's official website or consult financial news platforms for updates.
📊 Stock Investment Checklist (100 Points)
Cohance Lifesciences Ltd • Updated: 2025-09-17 06:30:17
-
10BusinessHighThe sector is evolving with increasing demand for healthcare solutions, but the company lacks a strong competitive moat.
-
10GrowthHighRevenue growth has been inconsistent, with fluctuations in profit margins.
-
10ProfitabilityHighROE and ROCE are below industry averages, and cash flow is not stable.
-
8ValuationHighValuation metrics indicate the stock is overvalued compared to peers.
-
6BalanceGoodThe company has a moderate debt level, but liquidity is a concern.
-
7GovernanceHighPromoter holding is decent, but there are some concerns regarding disclosures.
-
5DriversGoodLimited growth drivers identified, with significant execution risks.
-
5TechnicalsGoodMarket sentiment is weak, with low liquidity and negative price action.
Final Score & Verdict
Score 56 / 100
• Decent
Cohance Lifesciences Ltd shows potential in a growing sector, but faces challenges in profitability and valuation. Caution is advised.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 65/100
- Governance: 80/100
- Market Confidence: 72/100